Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
TMO 
Thermo Fisher Scientific Inc (TMO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/10/2025: TMO (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
31 Analysts rated it
Highly popular stock, broad analyst coverage, trusted insights, strong investor interest.
1 Year Target Price $554.6
1 Year Target Price $554.6
| 18 | Strong Buy |
| 7 | Buy |
| 6 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -11.11% | Avg. Invested days 32 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/10/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 166.80B USD | Price to earnings Ratio 25.26 | 1Y Target Price 554.6 |
Price to earnings Ratio 25.26 | 1Y Target Price 554.6 | ||
Volume (30-day avg) 31 | Beta 0.78 | 52 Weeks Range 385.46 - 625.84 | Updated Date 07/11/2025 |
52 Weeks Range 385.46 - 625.84 | Updated Date 07/11/2025 | ||
Dividends yield (FY) 0.42% | Basic EPS (TTM) 17.05 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 15.19% | Operating Margin (TTM) 17.75% |
Management Effectiveness
Return on Assets (TTM) 5% | Return on Equity (TTM) 13.7% |
Valuation
Trailing PE 25.26 | Forward PE 18.73 | Enterprise Value 186744143770 | Price to Sales(TTM) 3.89 |
Enterprise Value 186744143770 | Price to Sales(TTM) 3.89 | ||
Enterprise Value to Revenue 4.35 | Enterprise Value to EBITDA 16.42 | Shares Outstanding 377494016 | Shares Floating 376686075 |
Shares Outstanding 377494016 | Shares Floating 376686075 | ||
Percent Insiders 0.19 | Percent Institutions 92.52 |
Upturn AI SWOT
Thermo Fisher Scientific Inc
Company Overview
History and Background
Thermo Fisher Scientific was formed in 2006 through the merger of Thermo Electron and Fisher Scientific. Thermo Electron, founded in 1956, focused on analytical instruments. Fisher Scientific, founded in 1902, was a supplier of laboratory equipment and chemicals. The merged company provides a broad range of products and services for research, analysis, discovery, and diagnostics.
Core Business Areas
- Life Sciences Solutions: Offers a broad range of reagents, instruments, and consumables used in biological and medical research.
- Analytical Instruments: Provides instruments and related services for chromatography, mass spectrometry, and elemental analysis.
- Specialty Diagnostics: Develops and manufactures diagnostic test kits and reagents used in healthcare settings.
- Laboratory Products and Biopharma Services: Offers a wide range of laboratory equipment, consumables, and bioproduction services for pharmaceutical and biotech companies.
Leadership and Structure
Marc N. Casper serves as the Chairman, President and Chief Executive Officer. The company operates with a decentralized structure, with business units focused on specific markets and product lines.
Top Products and Market Share
Key Offerings
- Mass Spectrometers: Used for identifying and quantifying molecules in complex samples. Thermo Fisher is a major player in this market. Competitors include Agilent Technologies and Bruker. Revenue data isn't publically available.
- Chromatography Systems: Separate and analyze complex mixtures of chemicals. Competitors include Agilent Technologies, Waters Corporation. Revenue data isn't publically available.
- Cell Culture Products: A wide range of products used for growing and maintaining cells in the lab. Competitors include Danaher (Cytiva) and Merck (MilliporeSigma). Revenue data isn't publically available.
- PCR instruments: Systems for the polymerase chain reaction used to duplicate and study DNA segments. Competitors include QIAGEN and Bio-Rad Laboratories. Revenue data isn't publically available.
Market Dynamics
Industry Overview
The life sciences and diagnostics industries are experiencing growth driven by increasing R&D spending, aging populations, and the rise of personalized medicine.
Positioning
Thermo Fisher Scientific is a leading player in the industry due to its broad product portfolio, strong brand reputation, and extensive global reach.
Total Addressable Market (TAM)
Estimated at hundreds of billions of USD. Thermo Fisher Scientific is well-positioned to capture a significant portion of this TAM given its diverse offerings and market leadership.
Upturn SWOT Analysis
Strengths
- Broad product portfolio
- Strong brand reputation
- Extensive global reach
- Significant R&D investment
- Strong financial performance
Weaknesses
- High debt levels
- Integration challenges from acquisitions
- Exposure to economic cycles
- Customer concentration
Opportunities
- Growing demand for personalized medicine
- Increasing R&D spending
- Expansion in emerging markets
- Technological advancements in genomics and proteomics
- Further acquisitions
Threats
- Intense competition
- Price pressures
- Regulatory changes
- Disruptive technologies
- Economic downturns
Competitors and Market Share
Key Competitors
- DHR
- A
- WAT
Competitive Landscape
Thermo Fisher Scientific has a broader product portfolio than many of its competitors, giving it a competitive advantage. However, some competitors have stronger positions in specific market segments.
Major Acquisitions
PPD
- Year: 2021
- Acquisition Price (USD millions): 17400
- Strategic Rationale: Expanded the companyu2019s clinical research services offering.
Brammer Bio
- Year: 2019
- Acquisition Price (USD millions): 1700
- Strategic Rationale: Expanded the companyu2019s gene therapy manufacturing capabilities.
Growth Trajectory and Initiatives
Historical Growth: Thermo Fisher Scientific has achieved consistent growth through organic expansion and acquisitions.
Future Projections: Analysts project continued growth in the coming years, driven by favorable industry trends and the company's strong market position.
Recent Initiatives: Recent initiatives include investments in digital technologies, expansion in emerging markets, and acquisitions of complementary businesses.
Summary
Thermo Fisher Scientific is a strong player in the life sciences and diagnostics industries due to its diversified portfolio and strategic acquisitions. Its ability to integrate acquired companies effectively is crucial for future growth. The company needs to remain vigilant against competition and economic downturns, but its overall outlook is positive.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings (10-K, 10-Q), Investor presentations, Analyst reports, Industry publications
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Market conditions and company performance are subject to change. The market share data is based on estimates and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Thermo Fisher Scientific Inc
Exchange NYSE | Headquaters Waltham, MA, United States | ||
IPO Launch date 1978-01-13 | Chairman, President & CEO Mr. Marc N. Casper | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 125000 | Website https://www.thermofisher.com |
Full time employees 125000 | Website https://www.thermofisher.com | ||
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery and production of drugs and vaccines, as well as diagnosis of infections and diseases. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment includes clinical diagnostics offering liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, protein detection assays, and instruments; immunodiagnostics offers develops, manufactures, and markets complete blood test systems to support the clinical diagnosis and monitoring of allergy, asthma, and autoimmune diseases; microbiology offers dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; transplant diagnostics products include human leukocyte antigen typing and testing for organ transplant market; and healthcare market channel offers consumables, diagnostic kits and reagents, equipment, instruments, solutions, and services. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. It offers products and services through a direct sales force, customer-service professionals, electronic commerce, and third-party distributors under Thermo Scientific; Applied Biosystems; Invitrogen; Fisher Scientific; Unity Lab Services; and Patheon and PPD. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.